Antisense Therapy: A New Approach to Treat Diseases by Targeting Genes

What is it about?

This paper reviews a modern treatment approach called antisense oligonucleotide (ASO) therapy, which works by targeting genes at the molecular level. ASOs are short strands of DNA or RNA designed to bind to specific messenger RNA (mRNA) inside cells. By attaching to mRNA, they block the production of harmful proteins, effectively “switching off” disease-causing genes. The paper explains how this technology has advanced in recent years, especially in overcoming earlier challenges related to delivering these molecules into cells. As illustrated in the mechanism diagram on page 1, ASOs bind to mRNA and prevent it from being used by ribosomes, stopping protein production. It also reviews a wide range of medical applications. These include treatment approaches for viral infections (such as COVID-19 and HIV), neurological disorders (like Alzheimer’s and spinal muscular atrophy), cancer, cardiovascular diseases, and genetic disorders. The paper highlights several approved ASO-based drugs and ongoing clinical research, showing the growing importance of this technology in medicine.

Featured Image

Photo by Zhang liven on Unsplash

Photo by Zhang liven on Unsplash

Why is it important?

This work is important because it presents a cutting-edge therapeutic strategy that directly targets the root cause of diseases—gene expression—rather than just managing symptoms. The study is especially timely due to rapid advancements in genetic medicine and the increasing number of approved antisense drugs. It demonstrates how ASO therapy can be applied across multiple disease areas, including emerging infections like COVID-19, making it highly relevant to current global health challenges. By summarizing both current applications and future potential, the paper provides valuable insight into how antisense technology could transform modern medicine.

Perspectives